Clinical trials · New York
Schizophrenia clinical trials in New York
We’re tracking 32 recruiting schizophrenia studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07459647RecruitingPhase 2
Long-term study of ML-007C-MA for schizophrenia
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Cedarhurst, New YorkAges 18–65 - NCT07703670Recruiting
MicroRNA markers in first episode schizophrenia
This study looks at tiny molecules called microRNAs in the blood of people having their first episode of schizophrenia. It aims to find markers that could help guide treatment choices.
Glen Oaks, New YorkAges 15–40 - NCT07615426RecruitingPhase 1
Testing aticaprant with antipsychotic medication for schizophrenia
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
Cedarhurst, New YorkAges 18–55 - NCT07565428RecruitingPhase 3
Study of roluperidone for negative symptoms of schizophrenia
This trial tests a new medicine called roluperidone for people with schizophrenia who have ongoing negative symptoms (like low motivation or social withdrawal) but stable positive symptoms (like hallucinations). It aims to see if the drug helps with these symptoms and if it can reduce the chance of relapse compared to other medications.
New York, New YorkAges 18–55 - NCT07434479Recruiting
Virtual reality mindfulness for aggression in schizophrenia
This study tests whether a virtual reality mindfulness program can help people with schizophrenia who have problems with impulsive aggression. You would use a VR headset for relaxation exercises and answer questions about your mood and behavior.
New York, New YorkAges 18–64 - NCT07423546RecruitingPhase 1/Phase 2
Brain scan study of Cobenfy in schizophrenia
This study tests a new medication called Cobenfy (also known as trospium) using brain scans to see how it affects dopamine in people with schizophrenia. If you have schizophrenia and are not currently on antipsychotics, you may be able to join.
New York, New YorkAges 18–50 - NCT07410507RecruitingPhase 2
Study of Brenipatide for adults with schizophrenia
This trial tests an investigational drug called brenipatide for people with schizophrenia who are already on a stable medication regimen. The goal is to see if adding this drug helps reduce relapses.
New York, New YorkAges 18–55 - NCT07288567RecruitingPhase 3
KarXT for teens with schizophrenia
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
Great Neck, New YorkAges 13–17 - NCT07227818RecruitingPhase 3
Testing NBI-1117568 to prevent schizophrenia relapse
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
New York, New YorkAges 18–65 - NCT07184619RecruitingPhase 3
Evenamide for hard-to-treat schizophrenia (add-on study)
This trial tests a new medication, evenamide, added to your current antipsychotic treatment. It looks to see if it can help people whose schizophrenia has not responded well to standard therapies.
New York, New YorkAges 18 years+ - NCT07114874RecruitingPhase 3
A long-term study of a new drug for schizophrenia
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
New York, New YorkAges 18–65 - NCT06963034RecruitingPhase 3
Study of a new medicine for adults with schizophrenia
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
Staten Island, New YorkAges 18–65 - NCT06961968RecruitingPhase 3
Schizophrenia medication withdrawal study
This study tests whether patients with schizophrenia can safely stop or reduce their current medication without worsening symptoms. It is designed for people who need ongoing psychiatric care.
Staten Island, New YorkAges 18–65 - NCT06911931Recruiting
Visual perception study in schizophrenia and bipolar disorder
This study looks at how people with schizophrenia or bipolar disorder see the world. By comparing their visual perception to people without these conditions, researchers hope to learn more about how the brain processes what we see.
Rochester, New YorkAges 18–65 - NCT06502964RecruitingPhase 2
ALTO-101 study for schizophrenia cognitive symptoms
This study tests an experimental medication called ALTO-101 for people with schizophrenia who also have cognitive impairment (memory or thinking problems). It aims to see if the drug can improve these symptoms while you continue your current antipsychotic treatment.
New York, New YorkAges 21–55 - NCT05389787Recruiting
Brain stimulation to improve thinking in schizophrenia
This pilot study tests whether stimulating the cerebellum (a part of the brain) using TMS can improve brain function and thinking in people with schizophrenia. If you qualify, you may receive TMS and undergo brain/cognitive assessments to see whether it helps.
New York, New YorkAges 18–60 - NCT06229210RecruitingPhase 3
Lumateperone safety study for children with schizophrenia, bipolar, or autism
This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.
New York, New YorkAges 5–17 - NCT03817502RecruitingPhase 3
Cariprazine test for teens with schizophrenia
This trial tests whether cariprazine works and is safe for teens aged 13 to 17 with schizophrenia. It may help if your symptoms are still moderate to severe despite current care.
Buffalo, New YorkAges 13–17 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
New York, New YorkAges 10–17 - NCT05208190RecruitingPhase 4
Clozapine to prevent violence in schizophrenia
This trial tests whether clozapine can reduce repeat violent behavior in people with schizophrenia or schizoaffective disorder. Participants are randomly assigned to clozapine or usual care to see which approach works better for preventing violence.
New York, New YorkAges 18–65 - NCT07424404RecruitingPhase 3
Long-term safety study of a medication for psychiatric disorders in children and teens
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Great Neck, New YorkAges 5–17 - NCT07469384Recruiting
Brain stimulation study for schizophrenia using tDCS
This study tests whether a mild form of brain stimulation called tDCS (transcranial direct current stimulation) can help improve symptoms of schizophrenia or schizoaffective disorder. tDCS uses small electrodes on the scalp to gently stimulate brain areas involved in vision and thinking.
Orangeburg, New YorkAges 18–55 - NCT07379827Recruiting
A study on switching to KarXT for schizophrenia
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
Buffalo, New YorkAges 18 years+ - NCT07369154RecruitingPhase 3
Long-term safety study of an investigational schizophrenia medication
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
New York, New YorkAges 18–65
Schizophrenia trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting schizophrenia studies listed above.
- Neurocrine Clinical Site · 3 studies
- New York State Psychiatric Institute · 3 studies
- Local Institution - 0061 · 2 studies
- Manhattan Psychiatric Center · 2 studies
- Zucker Hillside Hospital · 2 studies
- Adams Clinical Harlem
- Alkermes Investigator Site
- Clinical Site
What taking part in a schizophrenia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Schizophrenia trials in other states
Common questions
- Are there schizophrenia clinical trials in New York?
- Yes. We're currently tracking 32 recruiting schizophrenia studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a schizophrenia study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New schizophrenia studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.